In this file:

 

         VIDO-InterVac Targets Two to Three Years for Development of Safe ASF Vaccine

         Boehringer Ingelheim's China-developed CSF live vaccine approved

 

 

VIDO-InterVac Targets Two to Three Years for Development of Safe ASF Vaccine

 

Dr. Volker Gerdts - Vaccine and Infectious Disease Organization

Farmscape for June 25, 2020

 

The Director and CEO of VIDO-InterVac is hopeful a safe and effective vaccine to protect pigs against African Swine Fever will be available within two to three years.

 

Researchers around the world are using various techniques to develop vaccines to protect pigs from African Swine Fever.

 

The approach being used by VIDO-InterVac involves inserting specific proteins from African Swine Fever into another harmless virus for delivery as a vaccine.

 

VIDO-InterVac Director and CEO Dr. Volker Gerdts says this approach is much safer than methods that use live virus.

 

Clip-Dr. Volker Gerdts-VIDO-InterVac:

 

You take certain genes from the African Swine Fever Virus and include them into a harmless virus, in a porcine adenovirus.

 

Adenoviruses are those viruses that normally don't cause disease in either humans or animals and so they can function as a vector, as a delivery method for the gene that you're interested in.

 

By putting genes of the African Swine Fever virus into an adenovirus, you then get them delivered and the adenovirus makes them as part of its own and the immune system of the pig recognises these proteins that belong to the African Swine Fever but are part now of this adenovirus.

 

The advantage is that you stimulate the immune response.

 

As the same time you don't have any clinical disease, any complications.

 

You're not working with the African Swine Fever Virus so it's a very good way of inducing good protective immune responses without actually using the live African Swine Fever virus.

 

more

https://www.farmscape.com/f2ShowScript.aspx?i=27318&q=VIDO-InterVac+Targets+Two+to+Three+Years+for+Development+of+Safe+ASF+Vaccine

 

 

Boehringer Ingelheim's China-developed CSF live vaccine approved

Ingelvac CSF MLV will be produced by company's Taizhou plant, and it is expected to be commercialized in early 2021.

 

Source: Boehringer Ingelheim

via National Hog Farmer - Jun 25, 2020

 

Boehringer Ingelheim is proud to announce that its China-developed classical swine fever live vaccine (C-strain, PK/WRL Cell Line Origin) (English trade name: Ingelvac CSF MLV) has recently obtained a "New Veterinary Drug Registration Certificate" from the Ministry of Agriculture and Rural Affairs of China. It is the first CSF live vaccine jointly developed by a multinational company and Chinese research institutes. It marks another milestone for Boehringer Ingelheim's "in China, for China," as the company is committed to providing innovative and high-quality swine vaccines for the Chinese swine industry, as well as holistic swine disease solutions to pig farms.

 

CSF is a highly contagious and lethal infectious disease in pigs. As the disease has caused huge economic losses to the pig farming industry, it is classified as Class A Animal Disease in China. Even though massive vaccination with CSF live vaccines in China are effectively controlling the outbreak of CSF, endemic and sporadic spread still exists.

 

Most CSF live vaccines currently available on the market can only be stored at -15 degrees Celsius for 18 months. Cold-chain transportation, storage and dilution all need a strict temperature control. The newly approved Ingelvac CSF MLV uses state-of-the-art microcarrier-based suspension culture and freeze-drying technologies to ensure high-titer virus, stable vaccine production process and controllable quality. It can be stored at 2 to 8 degrees Celsius for 24 months...

 

more

https://www.nationalhogfarmer.com/business/boehringer-ingelheims-china-developed-csf-live-vaccine-approved